QuadMedicine Cash Flow Statement

Financials in millions KRW. Fiscal year is January - December.

Millions KRW. Fiscal year is Jan - Dec.

Fiscal Year	FY 2025	FY 2024	FY 2023
Period Ending	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023
Net Income	-6,931	-4,968	-9,759
Depreciation & Amortization	3,296	3,153	2,071
Loss (Gain) From Sale of Assets	16.34	-	-
Stock-Based Compensation	281.42	608.42	1,456
Other Operating Activities	-69.88	-128.87	40.43
Change in Accounts Receivable	-706.73	-1,082	-6.41
Change in Other Net Operating Assets	-433.43	3,490	7,957
Operating Cash Flow	-4,547	1,072	1,760
Operating Cash Flow Growth	-	-39.09%	-
Capital Expenditures	-2,191	-3,286	-11,817
Sale (Purchase) of Intangibles	-224.45	-218.8	-95.1
Investment in Securities	-1,000	-10	4,760
Other Investing Activities	-120.28	66.23	-134.66
Investing Cash Flow	-4,313	-3,449	-7,286
Short-Term Debt Issued	-	500	-
Long-Term Debt Issued	-	800	5,800
Total Debt Issued	-	1,300	5,800
Long-Term Debt Repaid	-357.49	-313.44	-271.52
Net Debt Issued (Repaid)	-357.49	986.56	5,528
Issuance of Common Stock	25,789	7,000	537.1
Other Financing Activities	-	74.04	196.28
Financing Cash Flow	25,431	8,061	6,262
Foreign Exchange Rate Adjustments	-327.15	129.9	20.89
Net Cash Flow	16,244	5,814	757.16
Free Cash Flow	-6,738	-2,214	-10,056
Free Cash Flow Margin	-62.98%	-23.80%	-993.97%
Free Cash Flow Per Share	-701.89	-254.01	-1164.44
Cash Interest Paid	352.04	368.76	64.9
Cash Income Tax Paid	9.25	-17.81	4.46
Levered Free Cash Flow	-6,805	-2,182	-
Unlevered Free Cash Flow	-6,587	-1,951	-
Change in Working Capital	-1,140	2,408	7,951

Source: S&P Global Market Intelligence. Standard template. Financial Sources.